Genevant

What Genevant does

Genevant Sciences is a B2B technology licensing company focused on nucleic acid drug delivery, founded in 2018 as a spinout from Arbutus Biopharma and operating as a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV). The company's core technology is a Lipid Nanoparticle (LNP) delivery platform with over 20 years of development history that enables functional delivery of mRNA, siRNA, and gene editing payloads, and which is the delivery mechanism behind patisiran/ONPATTRO, the first and only approved systemic RNA-LNP product. Genevant also operates a Ligand Conjugate Delivery Platform featuring multivalent N-acetylgalactosamine (GalNAc) motifs for hepatocyte delivery and novel structures for extrahepatic organs, with next-generation endosomal release functionality demonstrating a 10x potency advantage in nonhuman primates.

Genevant monetizes its technology through nonexclusive licensing agreements with pharmaceutical and biotechnology counterparties. Deal structures include upfront payments, development and regulatory milestone payments, and tiered royalties, with total potential deal values ranging from $100 million to $238 million per partner. The company's patent estate covers over 700 issued or pending patents worldwide and is the foundation of an active patent enforcement program, including a March 2026 $2.25 billion global settlement with Moderna (comprising $950 million upfront and up to $1.3 billion contingent on appeal) and ongoing U.S. litigation against Pfizer/BioNTech. Manufacturing capability extends to kilogram-scale nucleic acid batches, supporting future commercialization by licensees.

Genevant serves a horizontal customer segment of pharmaceutical and biotechnology companies developing mRNA therapeutics, siRNA drugs, gene editing treatments, and self-amplifying RNA vaccines, with named partners including BioNTech, Novo Nordisk, Editas Medicine, Tome Biosciences, Korro Bio, Gritstone bio, Repair Biotechnologies, and Epitopea. In addition to licensing, Genevant is advancing two proprietary late-preclinical candidates: GNV069 (siRNA-GalNAc for liver fibrosis) and GNV705 (siRNA-GalNAc for acromegaly). The company maintains offices in Vancouver (Canada), Cambridge (USA), and Basel (Switzerland), with the latter serving as its European headquarters.

Name

Genevant

Legal name

Genevant Sciences, Inc.

Website

https://genevant.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Drug Delivery Technology Licensing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Patent Owners & Lessors (6794)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Lipid nanoparticle delivery
• Nucleic acid therapeutics
• RNA drug delivery
• LNP technology licensing
• SiRNA delivery platforms

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Genevant generates revenue by granting nonexclusive licenses to its LNP technology and other delivery platforms to pharmaceutical and biotechnology companies. Licenses cover specified fields and indications with upfront payments, development and regulatory milestones, and tiered royalties on future product sales.
2. Milestone Payments: Collaborations include upfront payments, contingent milestone payments tied to development, regulatory, and commercial achievements, and tiered royalties on product sales. Deals range from $100M to $238M+ in total potential value.
3. Settlement Proceeds: Genevant and Arbutus Biopharma received $950 million upfront payment from Moderna settlement in July 2026, with additional $1.3 billion contingent on favorable appellate ruling. Roivant receives approximately two-thirds of settlement proceeds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Genevant Sciences is a nucleic acid delivery technology company that develops and licenses proprietary Lipid Nanoparticle (LNP) and Ligand Conjugate delivery platforms enabling functional delivery of mRNA, siRNA, and gene editing payloads. The company generates revenue by granting nonexclusive licenses to pharmaceutical and biotechnology partners for use of its delivery platforms and patent estate in specified therapeutic fields, supplemented by two proprietary late-preclinical product candidates (GNV069 and GNV705).

Product overview

Genevant Sciences operates as a technology-focused nucleic acid delivery company offering two core proprietary platforms: the Lipid Nanoparticle (LNP) Delivery Platform and the Ligand Conjugate Delivery Platform. These platforms enable delivery of diverse nucleic acid payloads including mRNA, siRNA, and gene editing constructs. The company also maintains two proprietary late preclinical product candidates: GNV069 (siRNA-GalNAc for liver fibrosis) and GNV705 (siRNA-GalNAc for acromegaly). Genevant's business model centers on selectively licensing its platforms and technologies to pharmaceutical and biotechnology partners while advancing its own proprietary candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• LNP Delivery Platform
• Ligand Conjugate Delivery Platform
• GNV069
• GNV705

Quantifiable outcome

• First and only approved systemic RNA-LNP product (patisiran/ONPATTRO)
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, former core, major, significant and ongoing.

• Arbutus BiopharmacoreStrategic or Co-development Partner · 3 March 2026Ongoing strategic relationship where Arbutus is Genevant's exclusive licensee for LNP delivery technology. Arbutus retains ownership stake in and license agreement with Genevant. Both companies jointly pursued patent litigation against Moderna and Pfizer/BioNTech. Arbutus is evaluating return of capital to shareholders in Q3 2026 in conjunction with Moderna settlement payment. Ongoing litigation against Pfizer/BioNTech continues in the U.S.
• Modernaformer coreOthers · 3 March 2026$2.25 billion global settlement resolving all U.S. and international patent infringement litigation. Moderna to pay $950 million upfront (July 2026) and additional $1.3 billion contingent on Section 1498 appeal resolution. Moderna granted global nonexclusive license to Genevant LNP technology for SM-102-containing mRNA vaccines for infectious disease. Settlement includes judgment of infringement and no invalidity on four Genevant/Arbutus patents. Pfizer/BioNTech litigation remains ongoing.
• EpitopeamajorStrategic or Co-development Partner · 19 December 2024Collaboration and nonexclusive license agreement to develop novel mRNA-LNP immunotherapies targeting Epitopea's proprietary aberrantly-expressed tumor specific antigens (aeTSAs) called Cryptigens for an undisclosed oncology indication. Genevant eligible to receive up to $123.5 million in upfront and contingent milestone payments per product and tiered royalties ranging from mid to high single digits on future product sales.
• Editas MedicinemajorStrategic or Co-development Partner · 21 October 2024Collaboration and nonexclusive license agreement combining Editas Medicine's CRISPR Cas12a genome editing systems with Genevant's LNP technology for in vivo gene editing medicines directed to two undisclosed targets. Genevant eligible to receive up to $238 million in upfront and contingent milestone payments and tiered royalties on future product sales.
• Repair BiotechnologiessignificantStrategic or Co-development Partner · 26 September 2024Collaboration and nonexclusive license agreement combining Repair's Cholesterol Degrading Platform (CDP) mRNA technology with Genevant's LNP technology for development of potential novel treatment for atherosclerosis. Genevant eligible to receive up to $107 million in upfront and contingent milestone payments per product and tiered royalties ranging from mid to high single digits on future product sales.
• Tome BiosciencessignificantStrategic or Co-development Partner · 16 January 2024Collaboration and nonexclusive license agreement combining Genevant's LNP technology with Tome's programmable genomic integration (PGI) technology to develop in vivo gene editing treatment for an undisclosed rare monogenic liver disorder. Total deal value of $114.3 million plus tiered royalties on future product sales.
• Novo NordiskmajorStrategic or Co-development Partner · 6 November 2023Collaboration and nonexclusive license agreement combining Genevant's LNP technology with Novo Nordisk's mRNA-based megaTAL technology to develop in vivo gene editing treatment for hemophilia A. Agreement arose from exercise of option under prior agreement between Genevant and 2seventy bio subsequently assigned to Novo Nordisk.
• Gritstone biomajorStrategic or Co-development Partner · 15 August 2023Multi-year, multi-pathogen option-based agreement for non-exclusive license to Genevant's LNP technology for use with Gritstone bio's self-amplifying RNA (samRNA) vaccines. Genevant eligible to receive option maintenance and exercise fees in single digit millions, up to $136 million in contingent milestone payments per product (subject to increase for multi-pathogen products), and royalties ranging from mid to high single digits. Genevant LNP technology used in Gritstone's COVID-19 vaccine candidate behind BARDA award.
• Korro BiosignificantStrategic or Co-development Partner · 7 March 2023Collaboration agreement combining Korro's RNA editing platform with Genevant's LNP technology to develop therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). Terms not disclosed.
• Pfizer/BioNTechongoingOthersOngoing patent infringement lawsuit in the United States for use of Arbutus/Genevant LNP technology in Pfizer/BioNTech's Comirnaty COVID-19 vaccine. Comirnaty sales represent approximately 2/3 of global COVID-mRNA vaccine sales to date. Favorable Markman ruling issued in September 2025.
• Roivant SciencescoreOthersGenevant Sciences is a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV). Roivant hosts investor calls and manages capital allocation including share repurchase programs from settlement proceeds. Roivant holds ownership stakes in both Arbutus and Genevant.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arbutus Biopharma: Arbutus is Genevant's closest direct peer and exclusive licensee for LNP delivery technology. Both companies originated from the same nucleic acid delivery lineage, co-enforce the LNP patent estate (joint litigation with Moderna and Pfizer/BioNTech), and share economics from the $2.25B Moderna settlement.
• Acuitas Therapeutics: Acuitas develops ionizable lipid-based LNP technology for delivery of mRNA and other nucleic acid therapeutics and is the LNP supplier behind Pfizer/BioNTech's Comirnaty. It is the primary competing LNP platform company and the most direct functional peer to Genevant.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam pioneered GalNAc-conjugate siRNA delivery (the foundation of Genevant's Ligand Conjugate Platform) and is the leading commercial siRNA company. It is comparable as a broad incumbent in RNA-targeted delivery and therapeutics.
• Ionis Pharmaceuticals: Ionis is a leading RNA-targeted therapeutics company developing antisense oligonucleotides across multiple disease areas. While it uses different delivery chemistry, it is comparable as a broad incumbent in RNA-based drug development and represents the same end-customer profile as Genevant's platform.

Emerging players

• Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) develops microfluidic-based LNP formulation technology and instrumentation used by RNA therapeutics developers. It is comparable as an emerging platform player in LNP delivery, though more focused on tools/formulation equipment than therapeutic applications.
• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using its proprietary TRiM™ delivery platform that, like Genevant's Ligand Conjugate, targets extrahepatic tissues. It is comparable as an emerging player with its own delivery platform for nucleic acid therapeutics.
• CureVac: CureVac is an mRNA therapeutics company developing vaccines and therapeutics, with its own LNP formulation expertise. It is comparable as a nucleic acid medicines developer that could be a Genevant platform licensee or competitor.

Others

• BioNTech: BioNTech is both a Genevant licensee (nonexclusive LNP access) and the target of ongoing patent litigation (Comirnaty). It is comparable as a major customer/litigation counterparty in the LNP value chain.
• Moderna: Moderna is a Genevant licensee under the March 2026 settlement and former litigation counterparty. It is comparable as both a major customer (nonexclusive SM-102 LNP license for infectious disease mRNA vaccines) and a key historical plaintiff.
• Editas Medicine: Editas is a Genevant licensee (up to $238M, October 2024) combining its CRISPR Cas12a systems with Genevant's LNP for in vivo gene editing. It is comparable as a major licensing partner representing the in vivo gene editing customer profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/genevantsci
• LinkedInlinkedin.com/company/genevant

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genevant